Medical Design Briefs - September 2023 - 9

Launch of CORI Digital Tensioner
The CORI Digital Tensioner produces
a surgeon-defined, quantifiable force to
distract the knee joint, apply consistent
tension to the ligaments, and provide objective
gap data for procedure planning
and execution. A small clinical case series
showed that the digital tensioner reduced
variability of tensioning by 64 percent
when compared to a manual technique.
CORI was driven by accelerating at
the adoption of robotics. The company
also reached a development milestone
in March 2023 with the first surgical procedure
using the digital tensioner. This
device is the first in a series planned for
CORI.
The U.S. market is already showing what
this portfolio is capable of, said Nesmes. It
has had high single-digit growth, helping
to build a portfolio in orthopedics around
" best in class " and differentiate the company
from its competitors.
" We believe this will be a significant
work for the segment. This is the most
visible with cementless [implants] and
CORI's revision capability and will be
more evident in hips and trauma and extremities
over time, " she said.
Advancing procedural innovation in
robotic-assisted surgery, the CORI Digital
Tensioner is a differentiated technology
that helps solve challenges for surgeons.
It is the first and only ligament tensioning
device in robotic-assisted surgery to
assess joint laxity in the native knee before
performing bony resection. It provides
automatic collection of gap data at
a specified force through the full range
of movement. The device uses a software
interface that allows surgeons to choose
their preferred target force value.
Franchise Growth
Smith & Nephew's ENT franchise grew
10 percent in the first quarter despite
some ongoing external supply-chain
challenges and the impact of the COVID
wave in China, said Nesmes. Joint repair
grew 7.3 percent with strong performance
across all procedure types. Developing
new market segments and the
steady stream of innovation have been
key components of long-term growth in
sports medicine.
In biologics, the company's REGENETEN
Bioinductive Implant added
further growth as a driver in knee repair,
demonstrating new solutions for ligament
reconstruction. The implant is redefining
Medical Design Briefs, September 2023
Smith & Nephew's CORI Digital Tensioner lets surgeons measure the ligament tension in a knee prior to cutting
bone. (Credit: Smith & Nephew)
Smith & Nephew's PICO single-use negative pressure wound therapy system. (Credit: Smith & Nephew)
biological healing. It supports the body's
natural healing response to facilitate new
tendon-like tissue growth and changes the
course of rotator cuff disease progression.
Comprised of type 1 collagen, the system
is designed to address biological tendon
regeneration for everything from partial
thickness to massive rotator cuff tears.
It stimulates the body's natural healing
response to support new tendon growth
and disrupt disease progression. Derived
from highly purified bovine Achilles tendon,
it creates an environment that is
conducive to healing.
Arthroscopic enabling technologies,
for example, grew 9.1 percent in the first
quarter. Its Core COBLATION and the
ongoing ramp-up of FASTSEAL were
the major contributors, along with a soft
prior year comparator from supply constraints
in 2022.
Smith & Nephew expects moderation
of the growth rate during 2023 as end
markets approach more normalized levels.
However, ENT is an attractive growth
www.medicaldesignbriefs.com
area as the market recovers, despite facing
some ongoing supply challenges.
ENT growth of 30.8 percent also reflects
post-COVID recovery in tonsil and adenoid
procedures.
Advanced Wound Management
Despite also facing ongoing supply
challenges, advanced wound management
grew 7.9 percent. As in previous
quarters, Nesmes said that advanced
wound care delivered solid performance
across most major regions, with underlying
growth of 1 percent, compared
with the prior year. Bioactives grew 15.2
percent, with the primary driver being
double-digit growth in skin substitutes.
Nesmes pointed to the acquisition of
Osiris Therapeutics, Inc. as a good example
of the company's tuck-in M&A strategy,
because it both added to the growth
of the franchise and delivered attractive
financial returns. Osiris develops regenerative
medicine products including skin,
bone graft, and articular cartilage substi9

http://www.medicaldesignbriefs.com

Medical Design Briefs - September 2023

Table of Contents for the Digital Edition of Medical Design Briefs - September 2023